Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions

Laird, John R.; Schneider, Peter A.; Tepe, Gunnar; Brodmann, Marianne; Zeller, Thomas; Metzger, Christopher; Ramanathan, Krishnan; Scheinert, Dierk; Micari, Antonio; Cohen, David J.; Hong, Wang; Hasenbank, Melissa S.; Jaff, Michael R.; Investigators, In.Pact Sfa Trial

doi:10.1016/j.jacc.2015.09.063

Cited by 342 publications

(252 citation statements)

References 29 publications

Supporting

Mentioning

232

Contrasting

Unclassified

Order By: Relevance

“…[4][5][6] In addition to improved efficacy in terms of improvement of symptoms, time free from reintervention, and reductions in amputation rates, studies have also shown that the procedures have similar levels of safety, which is understandable considering the similar techniques employed.…”

Section: Discussionmentioning

confidence: 99%

O uso do balão com paclitaxel no tratamento da reestenose intra-stent no segmento fêmoro-poplíteo

Oliveira¹,

Peclat²,

Barreto³

et al. 2017

J. vasc. bras.

View full text Add to dashboard Cite

Background: In-stent restenosis due to myointimal hyperplasia after angioplasty is common and limits long-term patency. Treatments using balloons coated with antiproliferative drugs may offer an alternative option for this pathology. Objectives: To demonstrate the efficacy and complications (death, major amputations, etc.) of drug-coated balloons for treatment of in-stent restenosis in femoropopliteal segments. Methods: This was a retrospective cohort study of 32 consecutive patients treated between 2012 and 2016 who underwent treatment to correct in-stent restenosis in the femoropopliteal segment using paclitaxel-coated balloons. The success rate was measured in terms of technical success and restenosis of less than 50% on Doppler ultrasonography at 30, 90, and 180 days after the procedure. Results: Four patients (12.5%) exhibited restenosis greater than 50%, one (3.1%) after 90 days and three (9.4%) after 180 days, equating to a success rate of 87.5% of procedures, and by 180 days all patients experienced improvement or cessation of the signs and/or symptoms they had presented prior to the procedure. There were no deaths and complications occurred in just 2 cases in the immediate postoperative period. Conclusions: Short-term results are promising, with reductions in the magnitude of restenosis and a low rate of complications. Further studies are needed that can demonstrate the long-term effects and the economic impacts in comparison to other procedures.

show abstract

Section: Discussionmentioning

confidence: 99%

O uso do balão com paclitaxel no tratamento da reestenose intra-stent no segmento fêmoro-poplíteo

Oliveira¹,

Peclat²,

Barreto³

et al. 2017

J. vasc. bras.

View full text Add to dashboard Cite

show abstract

“…The rates of clinically directed target vessel revascularization (CD-TLR) were 9.1% and 28.3% (p < 0.001) for the DCB and PTA groups, respectively. The rate of vessel thrombosis was low (1.5% DCB vs. 3.8% PTA; p = 0.243), with no new events reported between 1 and 2 years [11]. The use of drug-coated balloons on the venous circulation has also been studied.…”

Section: Discussionmentioning

confidence: 99%

Percutaneous Management of Non Malignant Superior Vena Cava Syndrome Using IN.PACT Paclitaxel Coated Balloon

Iftikhar¹,

Gajo²,

Fisher³

et al. 2017

AJCTS

View full text Add to dashboard Cite

Superior Vena Cava (SVC) syndrome is an uncommon but known complication of Implantable Cardioverter Defibrillator (ICD) and pacemaker lead placement. In general 0.2 to 3% of all implants are associated with symptomatic SVC stenosis. Stent placement is a viable option for benign SVC syndrome in the absence of indwelling pacing leads. The risk of perforation and lead fracture increases when large numbers of leads are present chronically. We describe here a case of patient with SVC syndrome secondary to chronic ICD and pacemaker lead placement and a novel use of IN.PACT tm paclitaxel drug coated balloon to treat the SVC obstruction with a favorable clinical result.

show abstract

“…Beyond striking surgical arterial reconstructions [76][77][78][79], new tapered nitinol [81], drug-eluting stents (DES) [82], and original drugeluting balloon, (DEB) [83] were imagined. Novel or redesigned directional or rotational atherectomy devices [84], together with latest "bioresorbable scaffolds" technologies [85], represent few additional of numerous achievements that challenge today ancient technical barriers [1,29,75,[81][82][83][84][85][86].…”

Section: Contemporary Landmarks In Ischemic Wounds Revascularizationmentioning

confidence: 99%

“…Beyond high-performance techniques in reconstructing arterial flow [72][73][74][75][76][77][78][79][80][81][82][83][84][85][86], new strategies about "when" and "where" to perform appropriate revascularization emerge today [1,27,30,35]. Contemporary practitioners equally avail key data on the molecular mechanisms generating ischemic threat and tissue regeneration [59][60][61].…”

Section: New Strategies For "Wound Targeted Revascularization"mentioning

confidence: 99%

Ischemic Ulcer Healing: Does Appropriate Flow Reconstruction Stand for All That We Need?

Alexandrescu¹,

Triffaux²

2016

Wound Healing - New Insights Into Ancient Challenges

View full text Add to dashboard Cite

During the recent decades, soaring progresses in vascular disease knowledge, particularly in critical limb ischemia (CLI) treatment, enhanced novel diagnostic and interventional strategies with high serviceableness in patient's selection, arterial recanalization, and dedicated ischemic ulcer follow-up. However, despite undeniable advances in medical technology and clinical judgment, limb salvage, the ambulation recovery, and patient's survival seem only scarcely affected in this heterogeneous CLI group, particularly concerning the diabetic and renal patients. Innovative strategies such as "end artery occlusive disease" treatment or "wound-targeted revascularization" were equally proposed by following the angiosomal anatomical distribution associating individual foot collateral assessment in a unified macro-and micro-circulatory judgment. However, despite encouraging clinical results, prospective evidence still lacks on this concern. It also appears that specific wounds could not always stand for the lowest perfusion areas according to current CLI criteria, since severe neuropathy, inflammatory swelling, local infection, and skin trauma may add complementary hindrances to tissue viability.The present chapter endeavor to summarize main available treatment principles for ischemic ulcer recovery that every modern practitioner eventually disposes in an updated contemporary view."

show abstract

Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions

Cited by 342 publications

References 29 publications

O uso do balão com paclitaxel no tratamento da reestenose intra-stent no segmento fêmoro-poplíteo

O uso do balão com paclitaxel no tratamento da reestenose intra-stent no segmento fêmoro-poplíteo

Percutaneous Management of Non Malignant Superior Vena Cava Syndrome Using IN.PACT Paclitaxel Coated Balloon

Ischemic Ulcer Healing: Does Appropriate Flow Reconstruction Stand for All That We Need?

Contact Info

Product

Resources

About